Email Facebook Twitter

Looking for big risk, big reward investing? See our exclusive Pharma video series from 'Biotech and Money' Watch here

PHARMA: Heat Biologics - a 'potentially transformative' lung cancer treatment, Phase II data Q3 2018

Glaxosmithkline Share Price (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price: 1,297.00Bid: 1,296.50Ask: 1,297.00Change: -6.00 (-0.46%)Faller - Glaxosmithkline
Spread: 0.50Spread as %: 0.04%Open: 1,303.00High: 1,304.00Low: 1,295.50Yesterday’s Close: 1,303.00

Glaxosmithkline Plc Ord 25P

Glaxosmithkline is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Glaxosmithkline is part of the Medicine and Biotech Research sector

Glaxosmithkline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.

Share Price SpacerPrice

Share Price SpacerBid

Share Price SpacerAsk

Share Price SpacerChange

Share Price SpacerVolume

Share Price SpacerOpen

Share Price SpacerHigh

Share Price SpacerLow

Share Price SpacerClose

Share Price SpacerCurrency

Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 4,917.43m £63,779.09m 1,500

52 Week High 1,724.50 52 Week High Date 22-JUN-2017
52 Week Low 1,294.00 52 Week Low Date 21-NOV-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1,612 560,600 436,656 68.989 18.80 80.00 6.17

London South East Users info for Glaxosmithkline

Users who watch GSK also watch: BP, Lloyds, Vodafone, Tesco, Barclays, RBS, HSBC, BT, National Grid, Astrazeneca

Users who hold GSK also hold: Vodafone, BP, Lloyds, National Grid, Royal Dutch Shell B, Tesco, HSBC, Aviva, Centrica, BT

Trade Prc

Trade Type:

Trade Type:
Automatic execution

Trade Type:
Automatic execution

View more Glaxosmithkline trades >>

Directors Deals for Glaxosmithkline (GSK)
Trade DateActionNotifierPriceCurrencyAmountHolding
Trade Notifier Information for GlaxoSmithKline
Emma Walmsley held the position of CEO at GlaxoSmithKline at the time of this trade.
 Emma Walmsley
Trade Notifier Information for GlaxoSmithKline
Simon Dingemans held the position of CFO at GlaxoSmithKline at the time of this trade.
 Simon Dingemans
Trade Notifier Information for GlaxoSmithKline
Dominic Redfern held the position of Chief Strategy Officer at GlaxoSmithKline at the time of this trade.
 Dominic Redfern
View more Glaxosmithkline directors dealings >>

Date/TimeAuthorSubjectShare PriceOpinion
Today 09:16TLWilliams.Another positive announcement.1,297.50Hold
There has been a number of these recently, which renders the severe erosion of the share price questionable yo say the least.

GlaxoSmithKline said the US Food and Drug Administration has approved Juluca as a one pill a day maintenance treatment for adults with the HIV-1 infection. Glaxo's majority-owned subsidiary ViiV Healthcare, a specialist HIV company whose other stakeholders include Pfizer Inc and Shionogi Ltd, said Juluca has been approved as a treatment on a stable antiretroviral… Read More
Today 09:16OldThor23RE: GSK1,297.50No Opinion
Like you TL I'm retired too but clearly not as well cashed up, but that's life I am content. I try not to have regrets especially with regard to investing and we both know that it's a treacherous world out there. GSK is a good company doing some great and inspiring work. It's not been helped by Woodford Funds dumping their holdings. I believe the board was correct in not listening to his idea of breaking it up. Yes, there would have been short term profits but there is the problem with… Read More
Today 08:59TLWilliams.RE: Yesterday's RNS1,298.00Hold
I don£t read too much into yesterday£s announcement. Just another useful piece of information as far as I am concerned. I have already inserted these dates in my diary as I intend to remain invested in GSK over the coming year.
Today 08:54TLWilliams.RE: GSK1,297.50Hold
Well said OldThor23. I am heavily invested in GSK, having carried out extensive research beforehand, and agree with your thoughts about the future of the share price. My single regret is in misjudging the floor following the post Q3 drop in share price. I anticipated a low point in the 1430-1440 range when it started dropping and purchased just before that level. I did not anticipate such a severe fall, and still have difficulty in justifying it to myself. However, with the instability and… Read More
Today 07:42OldThor23GSK1,303.00No Opinion
A few weeks ago I posted on here adverse comments regarding Mrs. Walmsley and here leadership of the company. Pokerchump rightly pointed out that it is of course a tem lead business and I know that. Since then I have taken the time to study in detail the entire statement by the CEO along with all of the question and answer section. My opinion has changed and I think it was a good positive presentation by her, and her teams answers were both lucid, candid and to the point. I am no way a… Read More
Today 05:11skill58Yesterday's RNS1,303.00No Opinion
Feel like desperation to me. It guarantees nothing. Why release something that tells as close to nothing?

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Glaxosmithkline (GSK) >>

Please login or register to post a message on Share Chat.

Glaxosmithkline Plc Ord 25P home pageWebsite: Glaxosmithkline Plc Ord 25P
Website Description: GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of August 2016 it had a market capitalisation of £81 billion the fourth largest on the London Stock Exchange

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.